Effect of Dipeptidyl Peptidase-4 Inhibitors vs. Metformin on Major Cardiovascular Events Using Spontaneous Reporting System and Real-World Database Study
Explore this paper's citation graph
Summary
A comprehensive analysis using two different databases in Japan showed that DPP-4 inhibitors, which are widely used in Japan, have a non-inferior risk of cardiovascular events compared to metformin, which is used as the first-line drug in the United States and Europe.
- Type
- article
- Published
- 2022-08-25
- Cited by
- 7
- References
- 38
- Access
- Open access
- OpenAlex
- https://openalex.org/W4293217697
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:251875378
Keywords
Medicine, Metformin, Dipeptidyl peptidase-4, Saxagliptin, Pharmacology
References
- Meta-analysis of dipeptidyl peptidase-4 inhibitors use and cardiovascular risk in patients with type 2 diabetes mellitus.
- Japanese Clinical Practice Guideline for Diabetes 2016
- Metformin use and mortality among patients with diabetes and atherothrombosis.
- Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
- Metformin-inclusive therapy reduces the risk of stroke in patients with diabetes: a 4-year follow-up study.
- Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
- Psychosocial problems and barriers to improved diabetes management: results of the Cross‐National Diabetes Attitudes, Wishes and Needs (DAWN) Study
- Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
- Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
- 10-year follow-up of intensive glucose control in type 2 diabetes.
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
- Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.
- Incretin‐based drugs for type 2 diabetes: Focus on East Asian perspectives
- Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions
- Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis
- Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial
- Identification of 28 new susceptibility loci for type 2 diabetes in the Japanese population
- Comparing treatment intensification and clinical outcomes of metformin and dipeptidyl peptidase‐4 inhibitors in treatment‐naïve patients with type 2 diabetes in Japan
Cited by
- Psychiatric disorders associated with PCSK9 inhibitors: A real‐world, pharmacovigilance study
- A Non-Coronary, Peripheral Arterial Atherosclerotic Disease (Carotid, Renal, Lower Limb) in Elderly Patients—A Review PART II—Pharmacological Approach for Management of Elderly Patients with Peripheral Atherosclerotic Lesions outside Coronary Territory
- Comprehensive Cardiovascular Risk Profiling in People Living with HIV: Insights from the Japanese Adverse Drug Event Report Database
- Heterogeneity of Treatment Effects Across Nine Glucose-Lowering Drug Classes in Type 2 Diabetes: Extension of the LEGEND-T2DM Network Study
- Deep learning framework reveals drug combinations involving Dipeptidyl peptidase-4 inhibitors for treatment of Polycystic Ovarian Syndrome on a heterogeneous network
- Heterogeneity of Treatment Effects Across Nine Glucose-Lowering Drug Classes in Type 2 Diabetes: Extension of the LEGEND-T2DM Network Study
Related papers
- Efficacy and short-term side effects of sitagliptin, vildagliptin and saxagliptin in Chinese diabetes: a randomized clinical trial
- PDB15 - CARDIOVASCULAR SAFETY OF EMPAGLIFLOZIN VERSUS DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS: SYSTEMATIC LITERATURE REVIEW AND INDIRECT COMPARISONS
- Long-Term Health Care Costs Among Adults With Type 2 Diabetes Initiating Dpp-4 Inhibitors
- Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks
- DPP-IV inhibitor-associated arthralgias.
- Response to ACCME Letter to the Editor
- Quantitative Model of the Relationship Between Dipeptidyl Peptidase‐4 (DPP‐4) Inhibition and Response: Meta‐Analysis of Alogliptin, Saxagliptin, Sitagliptin, and Vildagliptin Efficacy Results
- Dipeptidyl peptidase-4 inhibitors: Comparative analysis of members of the group
- Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.